Potential new biomarkers for idiopathic pulmonary fibrosis

M. Roksandic Milenkovic (Belgrade, Republic of Serbia), J. Kotur Stevuljevic (Belgrade, Republic of Serbia), V. Ceriman (Belgrade, Republic of Serbia), V. Milenkovic (Belgrade, Republic of Serbia), D. Jovanovic (Belgrade, Republic of Serbia)

Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Session: Prognosis and biomarkers of idiopathic pulmonary fibrosis
Session type: E-poster session
Number: 817
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Roksandic Milenkovic (Belgrade, Republic of Serbia), J. Kotur Stevuljevic (Belgrade, Republic of Serbia), V. Ceriman (Belgrade, Republic of Serbia), V. Milenkovic (Belgrade, Republic of Serbia), D. Jovanovic (Belgrade, Republic of Serbia). Potential new biomarkers for idiopathic pulmonary fibrosis. 817

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005



Possible target genes in idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - PG9 - Molecular pathology and genetics in lung diseases
Year: 2007

Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (3) 00019-2016; 10.1183/23120541.00019-2016
Year: 2017



Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013

Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013

Validation of a novel prognostic tool for idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012

Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016


PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip
Source: ERS Lung Science Conference 2021
Year: 2021

Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013

IGFBP-2 a new interesting target in IPF
Source: International Congress 2016 – ILD pathogenesis
Year: 2016

Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (1) 1700379; 10.1183/13993003.00379-2017
Year: 2017



Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013

The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012

Evaluating disease severity in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017
Year: 2017